|Mr. Gregory J. Flesher||CEO & Director||N/A||N/A||1970|
|Dr. Catherine C. Turkel PharmD, MBA, Ph.D.||Pres||N/A||N/A||1961|
|Mr. Jon Kuwahara CPA||Sr. VP of Fin. & Admin.||N/A||N/A||1965|
|Ms. Christine G. Ocampo CPA||Consultant||N/A||N/A||1972|
Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.
Novus Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.